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Incidental findings such as meningioma are becoming increasingly prevalent. There is no 
consensus on the optimal management of these patients. The aim of this study was to 
examine the outcomes of patients diagnosed with an incidental meningioma who were treated 
with surgery or radiotherapy.  
Methods 
Single-center retrospective cohort study of adult pa ients diagnosed with an incidental 
intracranial meningioma (2007-2015). Outcomes recorded were post-intervention morbidity, 
histopathological diagnosis and treatment response.   
Results 
Out of 441 patients, 44 underwent treatment. Median age at intervention was 56.1 years (IQR 
49.6-66.5); 35 female and 9 males. The main indication for imaging was headache (25.9%). 
Median meningioma volume was 4.55 cm3 (IQR 1.91-8.61) and commonest location was 
convexity (47.7%). Six patients underwent surgery at initial diagnosis. Thirty-eight had 
intervention (34 surgery and 4 radiotherapy) after a median active monitoring duration of 24 
months (IQR 11.8-42.0). Indications for treatment were radiological progression (n=26), 
symptom development (n=6), and patient preference (=12). Pathology revealed WHO grade 
I meningioma in 36 patients and WHO grade II in four. The risk of postoperative surgical and 
medical morbidity requiring treatment was 25%. Early and late moderate adverse events 
limiting activities of daily living occurred in 28.6% of patients treated with radiotherapy. 
Recurrence rate following surgery was 2.5%. All meningiomas regressed or remained 
radiologically stable following radiotherapy.   
Conclusion 
The morbidity following treatment of incidental intracranial meningioma is not negligible. 
Considering most operated tumors are WHO grade I, tr atment should be reserved for those 






Arising from the arachnoid cap cells in the brain, meningiomas are the commonest primary 
intracranial tumors.1 Their management consists of surgery, radiotherapy, radiosurgery, and 
active clinical-radiological monitoring. Meningiomas presenting with focal neurological 
deficits and seizures have clear management algorithms; safe maximal resection being first 
line treatment.2 In contrast, there remains no clear consensus on the management of 
asymptomatic meningiomas diagnosed during radiological examination for non-specific 
symptoms or other diseases, often referred to as “incidental meningiomas”.2, 3 The 
widespread availability of magnetic resonance imaging (MRI) and computed tomography 
(CT) has led to an increased reporting of incidental findings, and patients are becoming the 
so-called Victims Of Modern Imaging Technology (VOMIT).4, 5 Incidental findings cause 
significant patient anxiety and distress which are compounded by the uncertainty faced by 
clinicians in their on-going management.6   
The IMPACT (Incidental Meningioma: Prognostic Analysis Using Patient Comorbidity and 
MRI Tests) study is a longitudinal analysis of clinical and radiological outcomes in a 
retrospective cohort of patients with incidental intracranial meningioma.7 Here we report the 
surgery and radiotherapy outcomes of patients included in the IMPACT study who underwent 
treatment at initial diagnosis or after a period of active monitoring. We examine post-
intervention morbidity, mortality and histopathological diagnosis and investigate the clinical 
and radiological variables associated with outcomes.  
Material and Methods 
The Institutional Review Boards at the authors’ institutions approved this study, which was 
conducted and reported based on recommendations of the STROBE (Strengthening the 
Reporting of Observational Studies in Epidemiology) statement.8  
Study design and baseline characteristics  
The IMPACT cohort comprised of adults (age ≥16 y) with a newly identified incidental 
asymptomatic meningioma between January 2007 and December 2015, with follow-up 
through to March 2018. Patients with radiation-induced and neurofibromatosis type 2–
associated meningiomas were excluded. Specific criteria for inclusion in this study were: 
patients who (i) had undergone surgery or radiotherapy during the study period, (ii) had 
adequate documentation in the medical records of tumor pathology, admission, operative and 
discharge details, and (iii) had pre- and postoperative imaging available. The study setting 
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was the Walton Centre NHS Foundation Trust, the only specialist stand-alone neuroscience 
hospital in the UK. It serves a catchment area of 3.5 million people and has service 
partnerships with 18 other hospitals.   
Baseline variables of interest and data sources  
Clinical variables included patient age at intervention, sex, the World Health Organization 
(WHO) performance status (PS) and the age-adjusted Charlson comorbidity index (ACCI),9, 
10 collected retrospectively from electronic and paper m dical records. 
Imaging factors included (i) calcification on non-contrast CT (diffuse/partial/absent), (ii) 
tumor signal intensity compared with the contralateral gray matter on T2-weighted or fluid 
attenuated inversion recovery (FLAIR) MRI (hypo/isohyper), (iii) peritumoral signal 
intensity in relation to tumor volume using the signal change present on T2/FLAIR MRI (0–
5%/6–33%/34–66%/67–100%), (iv) meningioma volume using the ABC/2 formula on 
contrast-enhanced T1-weighted MRI/CT: (A) maximum meningioma diameter on axial 
plane, (B) diameter perpendicular to (A), and (C) maxi um height on coronal/sagittal plane, 
(v) meningioma location, classed into non–skull base and skull base and further 
subcategorized according to the International Consortium on Meningioma (ICOM) 
classification system and (vi) proximity to major dural venous sinuses (separate [≤10 mm]/in 
direct contact with sinus wall/invading). All factors were recorded using last available pre-
intervention radiology apart from calcification status and tumor signal intensity which were 
noted using initial diagnostic scans.  
Intervention details and outcomes 
Treatment details included indication for interventio  (radiological progression/new symptom 
development/patient preference) and time to intervention. For patients who underwent 
surgery, the following was noted: (i) Simpson grade (as recorded by the surgeon in the 
operative notes), (ii) tumor grade (reclassified according to the WHO 2016 criteria11) and 
histological subtype, (iii) postoperative medical and surgical complications (Landriel-Ibañez 
Classification12), (iv) WHO PS postoperatively and (v) tumor recurrence on MRI. Simpson 
grades I–III denoted gross total resection (GTR), whilst subtotal resection (STR) was defined 
as grades IV–V. For patients who underwent stereotactic radiosurgery (SRS) and fractionated 
stereotactic radiotherapy (fSRT), the following was recorded: (i) mode of treatment 
(primary/adjuvant/salvage), (ii) total dose (Gray [Gy]), (iii) early and late (≥3 months) 
toxicity (assessed by Common Terminology Criteria for Adverse Events v5.0), (iv) WHO PS 
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post-intervention and (v) radiological tumor response during follow-up 
(progression/regression/stable disease). For fSRT, number of fractions and fractionated dose 
were noted.  
Statistical analysis  
Baseline patient demographics were expressed using descriptive statistics; normally 
distributed variables as mean (standard deviation [SD]) and skewed variables as median 
(interquartile range [IQR]). Statistical differences among outcome groups for categorical 
variables were examined using Chi-squared test, or Fisher’s exact test if group sizes were less 
than five. Normally distributed data were examined using the Student’s t-test. Skewed 
continuous data were assessed using the Mann-Whitney U t st. Differences were considered 
statistically significant at P<0.05. The five and 10-year cumulative incidence rates of primary 
outcome measures (intervention and recurrence) wereestimated using life-table statistics. 
Data were analysed using R v3.5.0. 
Neuro-oncology service and incidental meningioma practice 
The neuro-oncology service at our center serves a catchment population of 3.5 million 
peoples and treats over 500 brain tumor patients annually. There are seven subspecialized 
neuro-oncology surgeons and five radiation neuro-oncologists. Management decisions for 
meningioma are made by consensus within the neuro-onc l gy tumor board. Patients are 
considered for treatment if they become symptomatic, or if they are asymptomatic but 
showing evidence of meningioma growth on surveillance MRI. Age, performance status and 
comorbidities are also considered. Patients are informed of the board’s recommendation and 
counselled about each management option (surgery/radiotherapy/active monitoring) before 
making a shared care decision. Patients with asympto atic meningioma may express a 
preference to have the meningioma treated.  Surgical removal of meningioma is carried out as 
an elective procedure by a neuro-oncology surgeon. P st-operative CT is carried out on day 1 
to assess the level of cerebral edema and to note the presence of hemorrhage. A baseline MRI 
is carried out at 3 months post-surgery.  Following discharge from hospital, patients are 
followed-up clinically and radiologically in a specialized neuro-oncology clinic at appropriate 
intervals based on meningioma grade, extent of resection and clinical status. Radiotherapy 
parameters are determined by the radiation neuro-onc l gists and is delivered using modern 






Study population  
Figure 1 details the study population selection process. During an overall median follow-up 
duration of 55.0 months (IQR 37.0-80.0), 10.0% (n=44) underwent an intervention; six at 
initial presentation (due to patient preference) and 38 after a median active monitoring period 
of 24.0 months (IQR 11.8-42.0). The five- and 10-year intervention-free survival rates were 
90.0 and 87.0% respectively. Patient demographics and clinical characteristics are 
summarized in Table 1.    
Surgical outcomes  
Extent of resection, histopathology and recurrence  
Gross total resection was achieved in 92.5% (37/40) of patients. The three STRs (Simpson 
IV) (7.50%) were for superior sagittal sinus invading meningiomas, with two residuals 
(WHO grade I) treated with adjuvant radiotherapy (Table 4). For 36 (90.0%) patients, surgery 
revealed WHO grade I meningiomas of the following histological subtypes: meningothelial 
(n=11), psammomatous (n=8), fibrous (n=8), transitional (n=6), angiomatous (n=1), 
microcystic (n=1) and lymphoplasmacyte-rich (n=1). The remaining four (10.0%) were 
WHO grade II atypical meningioma with increased mitotic activity in three cases and 
microscopic brain invasion in one case. The five-year r currence free survival rate was 97.0% 
(median follow-up 35.5 months [IQR 23.0-44.8]). An atypical meningioma had early 
recurrence five months following GTR (Simpson III), which was treated with fractionated 
radiotherapy (54 Gy/30 fractions). The patient was followed-up for 37 months following 
radiation with no evidence of further recurrence before dying from a hospital-acquired 
pneumonia that was unrelated to their meningioma.  
Postoperative morbidity and performance status   
Neurosurgical complications requiring treatment (grades Ib-IIIb) occurred in 15.0% (6/40) of 
patients within 30 days of treatment (Table 2). Two patients had permanent neurological 
complications – both had meningioma invading the superior sagittal sinus. Five (12.5%) 
patients experienced grade Ia complications, which did not necessitate further medical or 
surgical intervention. Surgical complications occurred in six of 10 (60.6%) patients with 
peritumoral signal change compared to five out of 30 (16.7%) with no signal change 
(P=0.014). Nine (22.5%) patients experienced postoperative medical complications (grades 
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Ia-Ib), four of which required medical treatment (grade Ib). The two outcome groups 
(complications vs. no complications) did not statisically differ in baseline clinical 
characteristics (Table 3).  
Postoperatively 37 patients were PS 0-1.  Three patients (7.5%) had deterioration in 
performance status after treatment: two patients underwent GTR of parasagittal meningiomas 
(PS 3 & 4) and one patient (PS 2) underwent GTR of a posterior fossa meningioma in contact 
with the transverse sinus.  
Radiation treatment outcomes  
Radiotherapy treatment details and outcomes are summarized in Table 4. Four patients 
received fSRT and three had SRS. Radiation treatment was administered after a period of 
active monitoring (n=4), following subtotal surgical resection of grade I meningioma (n=2) 
and at early recurrence of a grade II meningioma within 5 months of surgery (n=1). All seven 
patients exhibited regression or stable disease during a median follow-up period of 31.0 
months (IQR 12.0-37.0). Maximum early toxicities were grade II in two (28.6%) patients. 
Two late grade II toxicities were also observed. Performance status post-intervention was 0-1 
for all patients.  
Case vignettes  
Case 1 
A 62-year old female patient (ACCI 3 and PS 0) was diagnosed with an asymptomatic left 
posterior parasagittal meningioma during MRI investigation of migraines. Patient was offered 
treatment (surgery/radiotherapy) or active monitoring and opted for the latter. Meningioma 
volume increased from 2.47 cm3 to 5.39 cm3 over the course of 4 years (Fig. 2). Considering 
the slow radiological progression and the persistence of headaches, the patient requested 
surgery. Day one postoperatively, the patient developed right-sided hemiparesis and focal 
seizures. CT demonstrated a large cerebral hematoma with surrounding oedema causing 
effacement of the pre- and post-central gyri (Fig. 2C). Pathology revealed a WHO grade I 
meningothelial meningioma. At the last follow-up appointment 32 months following surgery, 
there was no evidence of recurrence, and the performance status (PS=3) and hemiparesis 





A 58-year old female (ACCI 2 and PS 0) was found to have an asymptomatic left posterior 
fossa meningioma during MRI investigation of vertigo. Volume at initial diagnosis was 3.7 
cm3 and after 12 months of follow-up, volume increased to 6.9 cm3 with peritumoral edema 
and left-sided motor symptoms (Fig. 3). A shared decision to operate was made. Pathology 
revealed a WHO grade I fibrous meningioma. Day 1 post surgery, the patient became drowsy 
(↓ GCS). A CT revealed a hematoma causing mass effect (Fig. 3D), which required 
evacuation. At the last follow-up appointment 30 months postoperatively, patient was PS 0 
with no evidence of recurrence.     
Discussion  
Modern radiotherapy techniques and microsurgical resection are treatment options 
recommended by several authors as first-line for the management of incidentally-discovered 
intracranial meningiomas.13-16 In this study, the rate and nature of morbidities using both 
treatment modalities and the histopathological parameters of these tumors are strong 
arguments against treatment at initial diagnosis or ubsequent ‘soft’ indicators for treatment 
such as asymptomatic slow radiological progression.  
Post-intervention morbidity  
Previous reports have shown old age and co-morbidity to correlate with post-intervention 
morbidity and worse long-term neurological function.17, 18 Our cohort of incidental 
meningioma patients was on average younger and with a low burden of comorbidities, 
however, the risk of complications observed was higher than expected. Description of 
outcomes following surgery and radiotherapy for incidental intracranial meningioma is sparse 
and the limited number of reports on this topic lack systematic classification and reporting of 
morbidity.19, 20 The risk of complications in our study requiring treatment was 25%, similar to 
the risk following treatment of symptomatic meningioma.21 Therefore, the concept of 
prophylactic surgery or radiotherapy to avoid future clinical and radiological progression of 
all patients with incidental meningiomas is a somewhat flawed argument, particularly as only 
10-25% of patients will have growth necessitating itervention.7, 22 A recent study of the 
English National Cancer Registry also demonstrated that approximately a fifth of patients 
with ‘benign’ WHO grade I meningiomas were deceased after 10-years of surgery; over what 
one would expect without the disease.23 Moreover, surgical resection of a meningioma may 
8 
 
contribute to a reduced health related quality of life and lead to clinically meaningful 
impairment in several cognitive domains for up to 10 years following surgery.24 
Patient selection for treatment based on imaging parameters  
In keeping with the ‘meningiomics’ approach to personalised management,25 selection of 
appropriate patients for early intervention can be better delineated using existing prognostic 
models.7, 26 Almost half of meningiomas in this treated cohort demonstrated hyperintensity on 
MRI and some were associated with peritumoral signal ch nge indicative of vasogenic 
oedema. Whilst these meningiomas are predisposed to radi logical growth and clinical 
progression,27, 28 and underwent intervention in our study for such indications, the increased 
risk of treatment-related morbidity seen in both our series and other studies,29, 30 would justify 
continuing active monitoring until definitive progression (i.e. symptoms of severity that need 
treatment e.g. seizures or focal motor deficit) occurs. Larger meningiomas at presentation are 
correlated with progression during follow-up and increased operative morbidity risk26, 31; 
however, meningioma volume in our study did not have n impact on morbidity and only a 
few operated meningiomas (n=9, 21%) were >10 cm3. This reflects the fact that incidental 
meningiomas are typically smaller than symptomatic meningiomas and remain so throughout 
follow-up. Similarly, meningioma location and proximity to critical neuro-vascular structures 
ought to be considered and this has been incorporated into recent prognostic models of 
incidental meningioma growth.7 The treated incidental meningioma in this study were mainly 
non-skull base (n=30, 68%) and surgical adverse events occurred in 9 cases (30%) compared 
to only 14% (2/14) in skull bases meningioma.  Whilst this initially seems counter-intuitive 
since skull base meningiomas are more closely approximated to critical neuro-vascular 
structures, it serves to highlight the challenges as ociated with apparently straightforward 
convexity and parasagittal meningiomas.  These meningiomas often overlie motor, sensory or 
language cortex, have intimate relationships to cortical draining veins and the sagittal sinus, 
and can be prone to idiosyncratic post-operative cerebral edema.  A more conservative 
approach to these meningiomas is advised, and a cost-effectiveness study of early versus 
delayed (on evidence of progression) intervention and the impact on patient outcome and 
healthcare resources would help aid decision making for this group of patients.  
Choice of treatment intervention 
Most patients in our study who progressed underwent surgical resection whilst a minority 
were treated with radiotherapy. The majority of incidental meningiomas have a tumor volume 
less than 10 cm3 such that surgery and radiosurgery are both reasonable options to deliver 
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good control rates 32.  Ultimately, the decision will be based on availability of treatment 
facilities, physician experience, meningioma location and importantly patient preference. 
Following SRS, up to 14% of patients experience adverse events including epilepsy and 
cognitive deficits.16 These are closely related to the development of post-SRS peritumoral 
edema, which may be associated with parasagittal and parafalcine location.33, 34 This is 
postulated to be due to the breakdown of the tumor-brain interface complicated by venous 
compression and subsequent congestion.35, 36 These observations in addition to the surgical 
morbidity associated with meningioma invading the sinu  underlines the importance of 
including venous sinus invasion as a radiological criterion of disease progression in 
prognostic studies.37, 38   
Histopathology and behaviour following treatment 
Operated incidental meningiomas in our series were primarily WHO grade I with few tumors 
fulfilling WHO grade II criteria. There were no misdiagnosed metastatic tumors. Previous 
studies of incidental meningioma have shown that the vast majority (~94%) are WHO grade I 
and therefore active monitoring is entirely justified as the first line management.22 A DNA-
methylome based classification of meningioma has recently been developed to stratify 
symptomatic tumors into six distinct prognostic groups.39 Although we do not have 
methylation data for our cases, we postulate that most would fall into the benign methylation 
classes (e.g. MC ben-1), however, those that grew a more likely to be in the intermediate 
methylation class.  
Study strengths and limitations 
This is a single-center retrospective study of treated incidental intracranial meningiomas, 
which adds to the literature available on post-intervention morbidity and histopathological 
parameters enabling better decision making. Quality of life assessment could not be 
performed based on clinical notes available though it should be noted that most patients 
remained under follow-up with the majority reporting o change in clinical symptoms; this 
comes in support of the notion that most patients wi h an incidental meningioma lead normal 
lives – a supposition supported by the limited quality of life studies 40, 41. Although we did not 
investigate patient anxiety it is nevertheless an important factor that merits consideration in 
agreeing a management and follow up plan with patients.   With regards to generalizability, 
the study cohort having been derived from a tertiary nstitution, which solely serve a large 
population of 3.5 million, and the agreement with prior studies on variables associated with 
postoperative outcomes, adds to the strengths of this s udy. However, the external validity of 
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our analysis is limited by its meningioma population with case complexity which may not 
extrapolate to other centers and clinician and patients bias with determination of treatment 
options. 
Conclusions  
Incidental intracranial meningiomas are increasingly common and form a not insubstantial 
workload for neurosurgeons and neuro-oncologists. Considering the histopathological 
findings of operated meningiomas and the morbidity associated with surgery and radiation, 
prolonged active monitoring with MRI surveillance is the recommended management 
strategy. This is supported by the decrease in needof treatment intervention despite the rise in 
prevalence of new meningioma diagnoses.42 Details surrounding duration of observation and 
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Figure legends  
 
Fig. 1. Study population and indications for brain CT/MRI 
Fig. 2. (A) Coronal FLAIR MRI demonstrating a hyperintense left posterior parasagittal 
meningioma with a volume of 2.5 cm3 (blue arrow). (B) Over the course of 4 years of follow-
up, volume increased to 5.4 cm3. (C) Coronal non-contrast CT showing a left cerebral 
haematoma 1-day postoperatively causing effacement of the surrounding gyri (red arrow). 
(D) Coronal non-contrast CT 1-week following surgery demonstrating maturation of 
haemorrhage and surrounding oedema (3 red arrows).  
Fig. 3. (A) Axial T1+contrast MRI demonstrating a left squamous occipital meningioma with 
a volume of 3.7 cm3 (blue arrow). (B) Over the course of 12 months of follow-up, volume 
increased to 6.9 cm3. (C) axial CT showing a left hematoma (red arrow) with significant 
mass-effect on the left cerebellar hemisphere, fourth ventricle and brainstem. (D) Axial 











Table 1. Baseline clinical and imaging variables for the IMPACT cohort and patients who received 
intervention 




Age Median (IQR)  64.0 (55.0-72.5) 56.1 (49.6-66.5) 
Sex, N (%) Female   348 (78.9) 35 (79.5) 
 Male  93 (21.1) 9 (20.5) 
ACCI Median (IQR)  4 (3-6) 2 (1-4) 
 0-2  103 (23.4) 23 (52.3) 
 3-5  212 (48.1) 18 (40.9) 
 ≥6  126 (28.6) 3 (6.80) 
PS Median (IQR)  0 (0-1) 0 (0-0) 
 0-1  387 (87.8) 44 (100) 
 2-4  54 (12.2) 0 (0) 





26 (5.9) 26 (59.1) 
 New symptom 
development 
 
6 (1.4) 6 (13.6) 
 Patient preference   12 (2.7) 12 (27.3) 
Meningioma count, N 
(%) 
 
   
Single   426 (96.6) 44 (100) 
Multiple 2  13 (2.9) 0 (0) 
 3  1 (0.2) 0 (0) 
 4  1 (0.2) 0 (0) 
     
Volume* Median (IQR)  1.6 (0.6-4.0) 4.55 (1.9-8.6) 
 ≤10 cm3  420 (91.5) 35 (79.5) 
 >10 cm3  39 (8.5) 9 (20.5) 
Location, N (%)* Non-skull base Convexity 183 (39.9) 21 (47.7) 
  Parasagittal 77 (16.8) 5 (11.4) 
  Parafalcine 36 (8.2) 2 (4.50) 
  Tentorial 21 (4.6) 2 (4.50) 
  Intraventricular  5 (1.1) 0 (0) 
 Skull base Sphenoid wing 45 (9.8) 6 (13.6) 
 
 
Posterior fossa – 
lateral & posterior 
42 (9.2) 4 (9.1) 
  Anterior Midline 34 (7.4) 3 (6.8) 
 
 
Posterior fossa – 
midline  
16 (3.5) 1 (2.3) 
Calcification, N (%)* Diffuse  81 (17.6) 1 (2.3) 
 Partial   74 (16.1) 5 (11.4) 
 Absent   109 (23.7) 13 (29.5) 
 NA  195 (42.5) 25 (56.8) 




75 (16.3) 3 (6.80) 
 Iso  210 (45.8) 18 (40.9) 
 Hyper  119 (25.9) 23 (52.3) 




intensity, N (%)* 
0-5% 
 
373 (81.3) 34 (77.3) 
 6-33%  16 (3.5) 2 (4.50) 
 34-66%  13 (2.8) 5 (11.4) 
 67-100%  2 (0.4) 3 (6.80) 
 NA  55 (12.0) 0 (0) 
Venous sinus 
involvement, N (%)* 
No 
 
291 (63.6) 20 (45.5) 
 Yes Separate  49 (10.5) 4 (9.10) 
  In direct contact  98 (21.4) 12 (27.3) 
  Invaded  21 (4.6) 8 (18.2) 
Venous sinuses 
involved, N (%)† 
SSS 
 
95 (56.5) 14 (58.3) 
 CS  35 (20.8) 4 (16.7) 
 SS  21 (12.5) 3 (12.5) 
 TS  15 (8.9) 3 (12.5) 
 Torcula  2 (1.2) 0 (0) 
Abbreviations: NA=not available; CS=cavernous sinus; SSS=superior sagittal sinus; SS=sigmoid sinus; TS=transverse sinus    
Imaging parameters for the IMPACT cohort are at presentation, however they were recorded using last available pre-intervention 
radiology (apart from calcification status and tumor signal intensity) for the intervention cohort  
*The IMPACT cohort imaging parameters are for 459 meningiomas in 441 patients  




Table 2. Details of postoperative surgical complications   
Patient 













Persisted beyond 30 




1 Parasagittal Anterior 
GTR-II 
 
















Posterior fossa – 













4 Parasagittal Posterior 
STR-IV 
 






5 Sphenoid wing Lateral GTR-II I - Yes Seizure No Ib-T 
6 Convexity Posterior GTR-II I 
Cerebral 
abscess 
Yes Motor deficit No Ib-T 





- Yes Visual deficit Yes 
Ia-P 
 
8 Parasagittal Posterior STR-IV I - Yes Motor deficit Yes 
Ia-P 
 
9 Convexity Anterior GTR-I I 
CSF 
accumulation 
No NA No 
Ia-T 
 
10 Convexity Anterior GTR-III II Haemorrhage No NA No 
Ia-T 
 
11 Parafalcine Posterior STR-IV I Haemorrhage No NA No Ia-T 
Abbreviations: P=permanent; T=transient; NA=not applicable 






Table 3. Difference in clinical and radiological characteristics among the postoperative 
complication groups 
  Overall postoperative complications P 
  Yes (N=15) No (N=25)  
Age Median (IQR) 59.0 (49.5-66.8) 53.5 (49.0-64.8) 0.670 
Sex, N (%) Female 12 (36.4) 21 (63.6) 0.769 
 Male 3 (42.9) 4 (57.1)  
ACCI Median (IQR) 2 (1-3) 2 (2-4) 0.431 
  Postoperative surgical complications  
  Yes (N=11) No (N=29)  
Meningioma volume  Median (IQR) 7.84 (5.33-21.6) 3.68 (1.92-7.33) 0.077 
Meningioma location, N (%) Non-skull base 9 (31.0) 20 (69.0) 0.694 
 Skull base 2 (18.2) 9 (81.8)  
Peritumoral signal intensity, 
N (%)  
0-5% 
5 (16.7) 25 (83.3) 0.014 
 6-100% 6 (60.0) 4 (40.0)  
Venous sinus involvement, N 
(%) 
No 
3 (15.8) 16 (84.2) 0.163 








































1 56, F Convexity Anterior 0.50 Primary SRS 1 12.5 70 Regression Fatigue-1 Neuralgia-1 
Headache-1 
2 49, M Posterior 
fossa - 
midline  
Petro-clival 0.26 Primary SRS 1 12.5 12 Stable Vomiting-1 Paresthesia-1 




3.20 Primary fSRT 42 54/30 33 Stable Nausea-1 Headache-2 
4 67, F Sphenoid 
wing 
Medial 0.56 Primary fSRT 42 54/30 8 Regression Nausea-1 TN disorder-2 
Fatigue-2 
5 56, F Parasagittal Posterior NM Adjuvant SRS 1 12.5 31 Stable Fatigue-1 NR 
Paresthesia-1 
6 52, F Parafalcine Posterior NM Adjuvant fSRT 42 54/30 24 Stable Nausea-1 NR 
Fatigue-1 
Alopecia-2 
7 68, M Convexity Anterior NM Salvage fSRT 42 54/30 37 Stable Fatigue-1 Phantom pain-1 







ACCI, Age adjust Charlson comorbidity index 
CT, Computed tomography 
fSRT, Fractionated stereotactic radiotherapy  
GTR, Gross total resection 
Gy, Gray 
IMPACT, Incidental meningioma: prognostic analysis using patient comorbidity and MRI 
tests 
IQR, Interquartile range 
MRI, Magnetic resonance imaging  
PS, Performance status 
SD, Standard deviation 
SRS, Stereotactic radiosurgery  
STR, subtotal resection 
STROBE, Strengthening the reporting of observational studies in epidemiology  
VOMIT, Victims of modern imaging technology 
WHO, World Health Organization  
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